Navigation Links
Micromet Added to Russell 3000 Index
Date:6/29/2009

ault.asp.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. Five of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
2. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
3. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
4. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
5. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
6. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
7. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
8. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
9. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
10. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
11. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... (PRWEB) August 28, 2014 PrimeSource ... construction materials, selected SoundConnect to support ... cloud based audio and web conferencing platform GlobalMeet ... support PrimeSource’s employees’ needs. SoundConnect delivers award ... , PrimeSource Building Products will be utilizing ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Whitehouse Laboratories ... long term partnership with PTI Inspection Systems ... with state of the art leak testing method development ... art instruments currently available. As part of this agreement, ... High Voltage Leak Detection Instrument developed and manufactured ...
(Date:8/27/2014)... August 27, 2014 Green & Grow ... Series B funding and secured Otter Capital as a ... will accelerate commercialization of GGI’s Agriplier™ technology, building on ... , “Since our first meeting, we have been ... biological product space,” said Alan Sobba, President and CEO ...
(Date:8/27/2014)... In 2013, Lawrence Livermore ... National Security LLC (LLNS), was awarded more ... state-of-the-art laser system for the European Union's Extreme ... in the Czech Republic. , When commissioned to ... the " High repetition-rate Advanced Petawatt Laser System ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3
... Extension until February 3, 2009 to meet continued listing ... VSCP ) today announced that the Nasdaq Hearings ... the Nasdaq Capital Market and has,allowed the Company until ... price. The Panel,s decision represents the full extent of ...
... Inc., a,privately held biopharmaceutical company, announced today that ... executive vice president and chief,financial officer., "Bob ... 28 years of,financial management experience to Horizon, including ... private companies," said Timothy P.,Walbert, president and chief ...
... have used a wide variety of materials to build ... business, nanotechnology researchers can often be limited by the ... State University researcher Hao Yan has avoided these pitfalls ... nanostructures inside a living cell. , The results ...
Cached Biology Technology:Nasdaq Grants VirtualScopics' Request for Continued Listing 2Nasdaq Grants VirtualScopics' Request for Continued Listing 3Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer 2Using living cells as nanotechnology factories 2Using living cells as nanotechnology factories 3
(Date:8/27/2014)... is related to ability that we already possess. For ... more easily than learning how to hit a tennis ... Neural Basis of Cognition (CNBC)a joint program between the ... fundamental constraint in the brain that may explain why ... Aug. 28, 2014, issue of Nature , they ...
(Date:8/27/2014)... risk to Europe based upon a proxy for impact ... a ,big data, approach to scientific research. , The ... Health ranked the top 100 pathogens affecting humans and ... which, they believe, will help governments across the continent ... diseases, including as a result of climate change, and ...
(Date:8/27/2014)... deadly disease that exists as five strains, none of ... strains is the Sudan ebolavirus (SUDV). Although not the ... illness, even as recently as 2012. In a new ... , researchers now report a possible therapy that could ... Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain that ...
Breaking Biology News(10 mins):Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2
... graduate student at the Icahn School of Medicine at Mount ... "30 Under 30" list in "Science and Health." The ... transforming for the better, opening up to revolutionary new ideas ... . Ms. Shapiro, 25, a native of Rochester, New ...
... study in this month,s edition of the Journal of ... for melanoma, the most dangerous form of skin cancer. MicroRNA ... and which stay silent. Melanoma tends to lack microRNA-26a, which ... negative," says Yiqun Shellman, PhD, investigator at the CU Cancer ...
... of androgen deprivation therapies to prevent precancerous prostate abnormalities ... in men with precancers with specific genetic alterations, according ... Cancer Discovery , a journal of the American ... survival of prostate cancer cells are very dependent on ...
Cached Biology News:Mount Sinai grad student, 25, named to Forbes '30 Under 30' in Science and Healthcare 2Serendipity points to new potential target and therapy for melanoma 2Preventing prostate cancer through androgen deprivation may have harmful effects 2
Improves spot morphology and DNA binding to the slide resulting in increased hybridization signal. ID Clarifier: Optimized spotting solution for use with SigmaScreen APS Coated Slides for Microarrays...
... strength adhesive system which facilitates the easy removal ... either side of the frame are of differing ... has an easy release adhesive whereas the reverse, ... bond. This means that when the coverslip is ...
... description: Humidity wells in the base hold ... humidity and probe hydration around the edges ... the risk of waterbath contamination. This chamber ... waterbaths or hybridisation ovens. Linkage: This CLS ...
... cDNA Synthesis and Labeling Kit generates labeled ... First unmodified cDNA is made via a ... an Oligo(dT) primer. Unlike other methods, there ... the reverse transcription reaction. This unmodified cDNA ...
Biology Products: